Holen Sie sich die Stockscreener-App
0.698
10.16%
-0.0789
Handel nachbörslich:
.68
-0.018
-2.58%
Schlusskurs vom Vortag:
$0.7769
Offen:
$0.78
24-Stunden-Volumen:
331.90K
Relative Volume:
0.15
Marktkapitalisierung:
$10.63M
Einnahmen:
$2.73M
Nettoeinkommen (Verlust:
$-19.43M
KGV:
-0.307
EPS:
-2.2739
Netto-Cashflow:
$-17.91M
1W Leistung:
-17.23%
1M Leistung:
-49.05%
6M Leistung:
-47.91%
1J Leistung:
-51.86%
1-Tages-Spanne:
$0.665
$0.78
1-Wochen-Bereich:
$0.665
$0.869
52-Wochen-Spanne:
$0.64
$3.265
Traws Pharma Inc Stock (TRAW) Company Profile
Firmenname
Traws Pharma Inc
Sektor
Branche
Telefon
267-759-3680
Adresse
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
0.698 | 11.83M | 2.73M | -19.43M | -17.91M | -2.2739 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-18 | Eingeleitet | Guggenheim | Buy |
| 2018-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-27 | Eingeleitet | Laidlaw | Buy |
| 2015-07-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Traws Pharma Inc Aktie (TRAW) Neueste Nachrichten
Traws Pharma Company Profile & Introduction - Moomoo
Traws Pharma files prospectus for $139.2M mixed shelf offering - scanx.trade
TRAWTraws Pharma Inc Options - Finviz
Traws Pharma (TRAW) renews shelf for $139.2M unsold securities - Stock Titan
Price to book forward of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Price to sales forward of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Enterprise value to revenue forward of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Enterprise value to EBIT forward of Traws Pharma, Inc. – NASDAQ:TRAW - TradingView
Traws Pharma, Inc. Actuals & Estimates (NASDAQ:TRAW) - TradingView
TRAW Forecast — Price Target — Prediction for 2027 - TradingView
Traws Pharma, Inc. Actuals & Estimates (FWB:0T20) - TradingView
0T20 Forecast — Price Target — Prediction for 2027 - TradingView
Traws Pharma stock falls as UK regulator delays key flu study - MSN
Traws Pharma Inc. (TRAW) Edges Higher With Modest Gain; Key Resistance at $0.90 in FocusSentiment Extreme - dars.gov.et
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program - Sahm
Traws Pharma Inc (TRAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Traws Pharma updates influenza prophylaxis program guidance - grafa.com
Update on Traws Pharma (TRAW) Toxicology Data Submission - GuruFocus
Traws Pharma to Resubmit Influenza Prophylaxis Data to UK Regulators – Latest Update on Tivoxavir Marboxil Program 12 – Minichart - Minichart
Traws Pharma prepares new toxicology package for influenza drug - TipRanks
Traws Pharma (TRAW) plans Q3 2026 MHRA resubmission for Phase 2a flu study - Stock Titan
Why Did TRAW Stock Slump 28% After Hours? - Stocktwits
Traws Pharma Positions Long-Acting Antivirals for Influenza & Outbreak Threats as Sector Opportunities Expand - Streetwise Reports
Biopharma Co. Hits Regulatory Hurdle in High-Priority Bird Flu Program - Streetwise Reports
TRAWS PHARMA INC (TRAW) Stock Chart - ChartMill
Traws Pharma downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Traws Pharma Inc (TRAW) Institutional Confidence - TradingKey
TRAW Downgraded by HC Wainwright & Co. -- Price Target Adjusted to $1.00 - GuruFocus
H.C. Wainwright Downgrades Traws Pharma(TRAW.US) to Hold Rating, Cuts Target Price to $1 - Moomoo
Traws Pharma Inc (TRAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Traws Pharma Inc (TRAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Traws Pharma Inc (TRAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Traws Pharma Inc (TRAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Traws Pharma Inc (TRAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Traws Pharma Inc (TRAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Traws Pharma Inc (TRAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Traws Pharma (TRAW) Plunges Over 32%: Support Test and Liquidity ConcernsSentiment Extreme - newsline.com
Bandwidth, Traws Pharma and other big stocks moving lower in Monday's pre-market session - MSN
TRAW Downgraded by Ladenburg Thalmann -- Rating Changed to Neutr - GuruFocus
Traws Delays Influenza Study After UK Regulatory Setback - MyChesCo
Traws Pharma shares slide after UK regulator postpones influenza study - MSN
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study - Benzinga
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Micron, Nebius surge premarket; Traws Pharma tumbles By Investing.com - Investing.com India
Micron, Nebius surge premarket; Traws Pharma tumbles - Investing.com
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study - Yahoo Finance
Why is Traws Pharma stock tumbling today? By Investing.com - Investing.com Canada
Traws Pharma stock tumbles after UK regulator delays flu trial By Investing.com - Investing.com Canada
Traws Pharma gains after hantavirus drug development update amid cruise ship outbreak - MSN
Traws Pharma Defers Phase 2a Human Influenza Study After UK MHRA Review, Advances Alternative Antiviral Candidates 1 – Minichart - Minichart
Traws Pharma (TRAW) Delays Phase 2a Trial of Tivoxavir Marboxil - GuruFocus
Finanzdaten der Traws Pharma Inc-Aktie (TRAW)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):